IBDEI35K ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,50342,0)
;;=E89.6^^193^2490^29
;;^UTILITY(U,$J,358.3,50342,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50342,1,3,0)
;;=3^PostProcedural Adrenocortical Hypofunction
;;^UTILITY(U,$J,358.3,50342,1,4,0)
;;=4^E89.6
;;^UTILITY(U,$J,358.3,50342,2)
;;=^5003042
;;^UTILITY(U,$J,358.3,50343,0)
;;=L68.0^^193^2490^6
;;^UTILITY(U,$J,358.3,50343,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50343,1,3,0)
;;=3^Hirsutism
;;^UTILITY(U,$J,358.3,50343,1,4,0)
;;=4^L68.0
;;^UTILITY(U,$J,358.3,50343,2)
;;=^5009262
;;^UTILITY(U,$J,358.3,50344,0)
;;=M80.00XA^^193^2490^2
;;^UTILITY(U,$J,358.3,50344,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50344,1,3,0)
;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
;;^UTILITY(U,$J,358.3,50344,1,4,0)
;;=4^M80.00XA
;;^UTILITY(U,$J,358.3,50344,2)
;;=^5013363
;;^UTILITY(U,$J,358.3,50345,0)
;;=M81.0^^193^2490^3
;;^UTILITY(U,$J,358.3,50345,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50345,1,3,0)
;;=3^Age-Related Osteoporosis w/o Fx
;;^UTILITY(U,$J,358.3,50345,1,4,0)
;;=4^M81.0
;;^UTILITY(U,$J,358.3,50345,2)
;;=^5013555
;;^UTILITY(U,$J,358.3,50346,0)
;;=M85.80^^193^2490^26
;;^UTILITY(U,$J,358.3,50346,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50346,1,3,0)
;;=3^Osteopenia,Unspec Site
;;^UTILITY(U,$J,358.3,50346,1,4,0)
;;=4^M85.80
;;^UTILITY(U,$J,358.3,50346,2)
;;=^5014473
;;^UTILITY(U,$J,358.3,50347,0)
;;=N62.^^193^2490^5
;;^UTILITY(U,$J,358.3,50347,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50347,1,3,0)
;;=3^Gynecomastia
;;^UTILITY(U,$J,358.3,50347,1,4,0)
;;=4^N62.
;;^UTILITY(U,$J,358.3,50347,2)
;;=^5015790
;;^UTILITY(U,$J,358.3,50348,0)
;;=E66.3^^193^2490^27
;;^UTILITY(U,$J,358.3,50348,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50348,1,3,0)
;;=3^Overweight
;;^UTILITY(U,$J,358.3,50348,1,4,0)
;;=4^E66.3
;;^UTILITY(U,$J,358.3,50348,2)
;;=^5002830
;;^UTILITY(U,$J,358.3,50349,0)
;;=E89.1^^193^2490^31
;;^UTILITY(U,$J,358.3,50349,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50349,1,3,0)
;;=3^Postprocedural Hypoinsulinemia
;;^UTILITY(U,$J,358.3,50349,1,4,0)
;;=4^E89.1
;;^UTILITY(U,$J,358.3,50349,2)
;;=^5003036
;;^UTILITY(U,$J,358.3,50350,0)
;;=R73.03^^193^2490^33
;;^UTILITY(U,$J,358.3,50350,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50350,1,3,0)
;;=3^Pre-Diabetes
;;^UTILITY(U,$J,358.3,50350,1,4,0)
;;=4^R73.03
;;^UTILITY(U,$J,358.3,50350,2)
;;=^8295662
;;^UTILITY(U,$J,358.3,50351,0)
;;=E73.9^^193^2490^18
;;^UTILITY(U,$J,358.3,50351,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50351,1,3,0)
;;=3^Lactose Intolerance,Unspec
;;^UTILITY(U,$J,358.3,50351,1,4,0)
;;=4^E73.9
;;^UTILITY(U,$J,358.3,50351,2)
;;=^5002914
;;^UTILITY(U,$J,358.3,50352,0)
;;=H40.9^^193^2491^11
;;^UTILITY(U,$J,358.3,50352,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50352,1,3,0)
;;=3^Glaucoma,Unspec
;;^UTILITY(U,$J,358.3,50352,1,4,0)
;;=4^H40.9
;;^UTILITY(U,$J,358.3,50352,2)
;;=^5005931
;;^UTILITY(U,$J,358.3,50353,0)
;;=H26.9^^193^2491^7
;;^UTILITY(U,$J,358.3,50353,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50353,1,3,0)
;;=3^Cataract,Unspec
;;^UTILITY(U,$J,358.3,50353,1,4,0)
;;=4^H26.9
;;^UTILITY(U,$J,358.3,50353,2)
;;=^5005363
;;^UTILITY(U,$J,358.3,50354,0)
;;=H10.9^^193^2491^10
;;^UTILITY(U,$J,358.3,50354,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,50354,1,3,0)
;;=3^Conjunctivitis,Unspec
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI35K 3750 printed Sep 23, 2025@20:18:15 Page 2
IBDEI35K ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,50342,0)
+2 ;;=E89.6^^193^2490^29
+3 ;;^UTILITY(U,$J,358.3,50342,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,50342,1,3,0)
+6 ;;=3^PostProcedural Adrenocortical Hypofunction
+7 ;;^UTILITY(U,$J,358.3,50342,1,4,0)
+8 ;;=4^E89.6
+9 ;;^UTILITY(U,$J,358.3,50342,2)
+10 ;;=^5003042
+11 ;;^UTILITY(U,$J,358.3,50343,0)
+12 ;;=L68.0^^193^2490^6
+13 ;;^UTILITY(U,$J,358.3,50343,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,50343,1,3,0)
+16 ;;=3^Hirsutism
+17 ;;^UTILITY(U,$J,358.3,50343,1,4,0)
+18 ;;=4^L68.0
+19 ;;^UTILITY(U,$J,358.3,50343,2)
+20 ;;=^5009262
+21 ;;^UTILITY(U,$J,358.3,50344,0)
+22 ;;=M80.00XA^^193^2490^2
+23 ;;^UTILITY(U,$J,358.3,50344,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,50344,1,3,0)
+26 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
+27 ;;^UTILITY(U,$J,358.3,50344,1,4,0)
+28 ;;=4^M80.00XA
+29 ;;^UTILITY(U,$J,358.3,50344,2)
+30 ;;=^5013363
+31 ;;^UTILITY(U,$J,358.3,50345,0)
+32 ;;=M81.0^^193^2490^3
+33 ;;^UTILITY(U,$J,358.3,50345,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,50345,1,3,0)
+36 ;;=3^Age-Related Osteoporosis w/o Fx
+37 ;;^UTILITY(U,$J,358.3,50345,1,4,0)
+38 ;;=4^M81.0
+39 ;;^UTILITY(U,$J,358.3,50345,2)
+40 ;;=^5013555
+41 ;;^UTILITY(U,$J,358.3,50346,0)
+42 ;;=M85.80^^193^2490^26
+43 ;;^UTILITY(U,$J,358.3,50346,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,50346,1,3,0)
+46 ;;=3^Osteopenia,Unspec Site
+47 ;;^UTILITY(U,$J,358.3,50346,1,4,0)
+48 ;;=4^M85.80
+49 ;;^UTILITY(U,$J,358.3,50346,2)
+50 ;;=^5014473
+51 ;;^UTILITY(U,$J,358.3,50347,0)
+52 ;;=N62.^^193^2490^5
+53 ;;^UTILITY(U,$J,358.3,50347,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,50347,1,3,0)
+56 ;;=3^Gynecomastia
+57 ;;^UTILITY(U,$J,358.3,50347,1,4,0)
+58 ;;=4^N62.
+59 ;;^UTILITY(U,$J,358.3,50347,2)
+60 ;;=^5015790
+61 ;;^UTILITY(U,$J,358.3,50348,0)
+62 ;;=E66.3^^193^2490^27
+63 ;;^UTILITY(U,$J,358.3,50348,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,50348,1,3,0)
+66 ;;=3^Overweight
+67 ;;^UTILITY(U,$J,358.3,50348,1,4,0)
+68 ;;=4^E66.3
+69 ;;^UTILITY(U,$J,358.3,50348,2)
+70 ;;=^5002830
+71 ;;^UTILITY(U,$J,358.3,50349,0)
+72 ;;=E89.1^^193^2490^31
+73 ;;^UTILITY(U,$J,358.3,50349,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,50349,1,3,0)
+76 ;;=3^Postprocedural Hypoinsulinemia
+77 ;;^UTILITY(U,$J,358.3,50349,1,4,0)
+78 ;;=4^E89.1
+79 ;;^UTILITY(U,$J,358.3,50349,2)
+80 ;;=^5003036
+81 ;;^UTILITY(U,$J,358.3,50350,0)
+82 ;;=R73.03^^193^2490^33
+83 ;;^UTILITY(U,$J,358.3,50350,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,50350,1,3,0)
+86 ;;=3^Pre-Diabetes
+87 ;;^UTILITY(U,$J,358.3,50350,1,4,0)
+88 ;;=4^R73.03
+89 ;;^UTILITY(U,$J,358.3,50350,2)
+90 ;;=^8295662
+91 ;;^UTILITY(U,$J,358.3,50351,0)
+92 ;;=E73.9^^193^2490^18
+93 ;;^UTILITY(U,$J,358.3,50351,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,50351,1,3,0)
+96 ;;=3^Lactose Intolerance,Unspec
+97 ;;^UTILITY(U,$J,358.3,50351,1,4,0)
+98 ;;=4^E73.9
+99 ;;^UTILITY(U,$J,358.3,50351,2)
+100 ;;=^5002914
+101 ;;^UTILITY(U,$J,358.3,50352,0)
+102 ;;=H40.9^^193^2491^11
+103 ;;^UTILITY(U,$J,358.3,50352,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,50352,1,3,0)
+106 ;;=3^Glaucoma,Unspec
+107 ;;^UTILITY(U,$J,358.3,50352,1,4,0)
+108 ;;=4^H40.9
+109 ;;^UTILITY(U,$J,358.3,50352,2)
+110 ;;=^5005931
+111 ;;^UTILITY(U,$J,358.3,50353,0)
+112 ;;=H26.9^^193^2491^7
+113 ;;^UTILITY(U,$J,358.3,50353,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,50353,1,3,0)
+116 ;;=3^Cataract,Unspec
+117 ;;^UTILITY(U,$J,358.3,50353,1,4,0)
+118 ;;=4^H26.9
+119 ;;^UTILITY(U,$J,358.3,50353,2)
+120 ;;=^5005363
+121 ;;^UTILITY(U,$J,358.3,50354,0)
+122 ;;=H10.9^^193^2491^10
+123 ;;^UTILITY(U,$J,358.3,50354,1,0)
+124 ;;=^358.31IA^4^2
+125 ;;^UTILITY(U,$J,358.3,50354,1,3,0)
+126 ;;=3^Conjunctivitis,Unspec
